The size of the Europe Plasma Fractionation Market is estimated to value USD 6.15 billion in 2021. It is projected to be growing at a CAGR of 6.10% to touch USD 8.27 billion by 2026.
Plasma fractionation is a technique for extracting plasma derivatives using a separation method. Albumin and immunoglobulins are two examples of plasma derivate available on the market. These products contain concentrated fractions of plasma protein, which are isolated from plasma obtained from many donors using fractionation. Plasma fractionation has become more popular as the older population has grown. This age group is particularly susceptible to various age-related disorders that necessitate various plasma protein therapies.
The growth of the European Plasma Fractionation Market is mainly driven by factors such as the increasing incidence of immune and bleeding disorders, the growing incidence of Alpha-1 Antitrypsin deficiency, and the rising use of immunoglobulins. Further, an increasingly aging population with related blood-related ailments is set to promote market growth. Additionally, the growing use of immunoglobulins in various therapeutic domains, expanding elderly population coupled with the rising frequency of rare diseases, and an increasing number of plasma collection sites are expected to be driving the market expansion. Furthermore, the rising prevalence of chronic neurological disorders, rheumatoid arthritis, and osteoarthritis have contributed to a rise in people who require modern therapies.
However, adverse reactions to plasma fractionation and transfer, high plasma product costs, ineffective reimbursement systems, and the rising use of recombinant alternatives are major market growth stumbling blocks.
Impact of COVID-19 on the European plasma fractionation market:
Following the WHO’s declaration of COVID-19 as a pandemic, countries worldwide implemented statewide lockdowns to enforce social separation as a preventative precaution. In every industry, this causes disruption, limits, challenges, and adjustments. The pandemic influenced the plasma fractionation business as well. The COVID-19 pandemic has resulted in a decline in blood donations and plasma collection, hating market growth due to a shortage of raw materials.
As the elective surgical procedure was postponed and care for other medical illnesses was similarly hampered, a loss in raw material supply was balanced by decreased demand for plasma derivatives at the commencement of nationwide lockdowns.
This research report on European Plasma Fractionation Market has been segmented and sub-segmented into the following categories:
By End User:
Geographically, Europe comes second in terms of market share in the global market due to greater awareness of blood-related illnesses and the speedy availability of therapy in terms of plasma fractionation. Furthermore, due to the rising occurrence of rare diseases in Europe, the region is expected to increase rapidly during the projection period. In addition, the market will benefit from the significant investments in plasma fractionation systems.
As part of developing plasma-derived therapy for treating the COVID-19 virus, the firms collaborate closely with hospitals. As a result, the hospitals and clinics segment is expected to occupy the greatest proportion of the global plasma fractionation market, based on the end-user. The expanding need for therapies for immunodeficiency disorders, the rising number of hospitals and healthcare expenditure, and the rising consumption of plasma-derived products by hospitals and clinics are all driving this segment’s rise. The market is divided into two-sector, the private sector, and the public sector.
Due to the technical advancements, the rate of diagnosis of a variety of immunological illnesses has increased. Furthermore, due to the increased number of diagnosed patients, increased genetic research for characterizing and diagnosing immunodeficiency will increase the clinical need for immunoglobulins.
The German plasma fractionation market is expected to lead the European market during the forecasting period.
KEY MARKET PLAYERS:
A few of the noteworthy companies operating in the European plasma fractionation market profiled in the report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Fractionation Process
5.1.4 Coagulation Factor Concentrates
5.1.6 Protease Inhibitors
5.1.7 Y-o-Y Growth Analysis, By Product
5.1.8 Market Attractiveness Analysis, By Product
5.1.9 Market Share Analysis, By Product
5.2.5 Critical Care
5.2.9 Other Application
5.2.10 Y-o-Y Growth Analysis, By Application
5.2.11 Market Attractiveness Analysis, By Application
5.2.12 Market Share Analysis, By Application
5.3 End User
5.4.3 Clinical Laboratories
5.4.4 Academic Institutes
5.4.5 Y-o-Y Growth Analysis, By End User
5.4.6 Market Attractiveness Analysis, By End User
5.4.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product
126.96.36.199 By Application
188.8.131.52 By Indication
6.1.4 Market Attractiveness Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Product
18.104.22.168 By Application
22.214.171.124 By End User
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Product
184.108.40.206 By Application
220.127.116.11 By End User
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Baxalta Incorporated
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 CSL Ltd.
8.3 Grifols S.A
8.4 Octapharma AG
8.5 Kedrion S.p.A
8.6 Bio Products Laboratory
8.8 China Biologic Products, Inc.
8.9 Biotest AG
8.10 Laboratoire Français du Fractionnement et des Biotechnologies
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures